China Pharma Holdings acquires dry eye disease therapeutic device project - BSA bureau

China Pharma Holdings has announced the acquisition of adust oculus illness (DED) therapeutic instrumentality project. This instrumentality has a patent.

Epidemiological probe shows that the incidence complaint of DED is astir 25% to 30%, and the incidence complaint of radical implicit 65-year-old is 75% in China. According to the Research Report connected the Market Status of the Global Dry Eye Disease Drug Industry successful 2022, the marketplace size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately $0.55 billion), resulting a 12.4% year-on-year growth.

In the tract of DED and ocular fatigue, this merchandise volition capable successful the marketplace spread of aesculapian therapeutic apparatus.

Li Zhilin, CEO of China Pharma said, "Due to the progressively developed technology, the clip and frequence of utilizing the physics products person importantly accrued successful caller years. In addition, with the aging of the population, DED has go the largest ophthalmic illness in China, and the diagnosis and attraction complaint is expected to support an upward inclination for a agelong time. What we acquired is an ophthalmic oxygen enriched atomization therapeutic instrumentality with a patent technology. This instrumentality is to capable successful the vacuum of the existent marketplace request successful devices to dainty DED, ocular fatigue and different problems, arsenic good arsenic betterment aft oculus surgery. We program to motorboat it to the marketplace adjacent year. We are assured that the motorboat of this merchandise volition bring fantabulous attraction acquisition to each DED patient, which volition besides boost the company's sales. "